Foresee Pharmaceuticals Receives China NMPA Approval for CAMCEVI® in Advanced Prostate Cancer Treatment

Foresee Pharmaceuticals Gains Approval in China for CAMCEVI® 42 mg

Foresee Pharmaceuticals, a leading biopharmaceutical company based in Taiwan, has marked a significant milestone in its international operations. On October 12, 2026, the company announced that its member, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci), received the Marketing Authorization Application (MAA) approval from China's National Medical Products Administration (NMPA) for CAMCEVI® 42 mg. This ready-to-use six-month subcutaneous depot formulation of leuprolide mesylate is set to be used for treating adult patients who are facing advanced prostate cancer.

Dr. Ben Chien, the Chairman and CEO of Foresee Pharmaceuticals, expressed his enthusiasm about this development, noting, "We are pleased that our partner GenSci will be launching CAMCEVI® 42 mg in China. These efforts will significantly contribute to the growth of our global CAMCEVI® franchise." This highlights the company's commitment to enhancing its product availability in strategic international markets, thereby allowing a greater number of patients access to innovative therapies.

CAMCEVI® is not just a singular product; it represents a vital part of Foresee's ongoing efforts to expand its market reach. GenSci has the exclusive rights to commercialize CAMCEVI® across all its current and future indications in China. These include not only advanced prostate cancer but also central precocious puberty (CPP) and premenopausal breast cancer, marking a comprehensive approach to treating various endocrine-related conditions.

In addition, GenSci submitted a supplemental New Drug Application (sNDA) in May 2026 for an injectable emulsion formulation of leuprolide mesylate targeting premenopausal breast cancer, which is now under substantive review by the NMPA. This proactive strategy underscores the commitment of both Foresee and GenSci to meet the diverse healthcare needs of patients in China.

About CAMCEVI® 42 mg

CAMCEVI® 42 mg offers a unique, sustained-release formulation of leuprolide mesylate, classified as a gonadotropin-releasing hormone (GnRH) agonist, that promises a less frequent administration schedule compared to standard therapies. This innovation is designed to improve adherence by simplifying the treatment process for patients suffering from advanced prostate cancer.

Prior to gaining approval in China, CAMCEVI® already achieved significant market penetration in areas such as the United States, European Union, Taiwan, and Israel, where it was approved in the U.S. back in May 2021 and has been received positively in subsequent markets. However, it's essential to note that the product labeling and approved uses may differ from one country to another, so healthcare providers are encouraged to consult local prescribing guidelines.

Future Outlook

The announcement regarding the NMPA approval for CAMCEVI® highlights Foresee Pharmaceuticals' ambitious expansion strategy. As they continue to innovate and develop their product pipeline, the company is also exploring new therapeutic avenues leveraging their proprietary Stabilized Injectable Formulation (SIF) technology.

Currently, Foresee's portfolio includes a range of early and late-stage programs. Their long-acting injectable product for treating central precocious puberty has reached a critical clinical development milestone, with plans for an NDA submission in the United States set for the latter half of 2026. Additionally, the company is also venturing into targeting the central nervous system (CNS) market, signifying a multi-billion-dollar growth opportunity on the horizon.

Furthermore, Foresee’s approach to developing therapies that respond to unmet medical needs is commendable. Their focus on rare and severe diseases highlights a commitment to making impactful contributions within the biopharmaceutical industry. Technologies such as the MMP-12 inhibitors underline the company's goal to address significant health conditions, seeing promising advances in various clinical trials.

As we look ahead, the NMPA’s endorsement of CAMCEVI® 42 mg signifies not just a business achievement for Foresee Pharmaceuticals, but also a hopeful future for many patients battling advanced prostate cancer in China. With GenSci at the helm for launch and commercialization, the collaboration signifies a robust step towards enhancing healthcare accessibility in the region.